Poland
· Delayed Price · Currency is PLN Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of PLN 98.74 million. The enterprise value is 95.60 million.
| Market Cap | 98.74M |
| Enterprise Value | 95.60M |
Important Dates
The next estimated earnings date is Tuesday, February 11, 2025.
| Earnings Date | Feb 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomtec has 13.32 million shares outstanding. The number of shares has increased by 18.87% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 13.32M |
| Shares Change (YoY) | +18.87% |
| Shares Change (QoQ) | -7.41% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 5.56% |
| Float | 10.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 10.41 |
| P/TBV Ratio | 10.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.26 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.81 |
Financial Position
The company has a current ratio of 2.39, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.39 |
| Quick Ratio | 2.13 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -102.57 |
Financial Efficiency
Return on equity (ROE) is -115.84% and return on invested capital (ROIC) is -56.09%.
| Return on Equity (ROE) | -115.84% |
| Return on Assets (ROA) | -38.28% |
| Return on Invested Capital (ROIC) | -56.09% |
| Return on Capital Employed (ROCE) | -80.84% |
| Revenue Per Employee | 59 |
| Profits Per Employee | -680,941 |
| Employee Count | 17 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.57% in the last 52 weeks. The beta is 0.25, so Genomtec's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -26.57% |
| 50-Day Moving Average | 7.49 |
| 200-Day Moving Average | 9.36 |
| Relative Strength Index (RSI) | 42.72 |
| Average Volume (20 Days) | 34,999 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of PLN 1,000 and -11.58 million in losses. Loss per share was -0.87.
| Revenue | 1,000 |
| Gross Profit | -2.63M |
| Operating Income | -11.28M |
| Pretax Income | -11.46M |
| Net Income | -11.58M |
| EBITDA | -8.92M |
| EBIT | -11.28M |
| Loss Per Share | -0.87 |
Balance Sheet
The company has 6.18 million in cash and 3.04 million in debt, giving a net cash position of 3.13 million or 0.23 per share.
| Cash & Cash Equivalents | 6.18M |
| Total Debt | 3.04M |
| Net Cash | 3.13M |
| Net Cash Per Share | 0.23 |
| Equity (Book Value) | 9.48M |
| Book Value Per Share | 0.71 |
| Working Capital | 4.85M |
Cash Flow
In the last 12 months, operating cash flow was -9.68 million and capital expenditures -59,000, giving a free cash flow of -9.74 million.
| Operating Cash Flow | -9.68M |
| Capital Expenditures | -59,000 |
| Free Cash Flow | -9.74M |
| FCF Per Share | -0.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,128,300.00% |
| Pretax Margin | -1,145,800.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.87% |
| Shareholder Yield | -18.87% |
| Earnings Yield | -11.72% |
| FCF Yield | -9.87% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 4.46.
| Altman Z-Score | 4.46 |
| Piotroski F-Score | n/a |